Industry Awareness
Although the investing community considers Telesta a stay away at all costs company, the Urology community at large would certainly be much more familiar with MCNA than they would have been just 12 months ago. While the Adcomm meeting and BLA submissions were unsuccessful they, along with the AUA coverage, would have drawn alot of attention to the treatment and CR and safety profile of P3a. This should bode well, from an acceptance and willingness to utilize stanpoint, for whoever buys the pending P3b and starts recruiting patients. I could be mistaken, but it is not everyday that a BLA gets this close in a market that hasn't seen an approval in 20 years. A google search says few knew about the BLA and fewer cared about is demise, but I am not sure that is true in the Urology and patient community